Hyperion Therapeutics Elects Lota Zoth to Board of Directors

04/07/08
Back To Press & Events
Hyperion Therapeutics, Inc., a privately held biopharmaceutical company, today announced that Lota S. Zoth has been elected to the company’s Board of Directors.


South San Francisco, CA - April 7, 2008 - Hyperion Therapeutics, Inc., a privately held biopharmaceutical company, today announced that Lota S. Zoth has been elected to the company’s Board of Directors. Ms. Zoth formerly served as Senior Vice President and Chief Financial Officer of MedImmune, Inc. with oversight of finance, information technology and public affairs.

In discussing her appointment, Ms. Zoth commented, “Hyperion’s co-promotion agreements and strong product pipeline make it a very attractive opportunity. I look forward to helping the Hyperion team continue to execute on its growth objectives."

Prior to MedImmune, Ms. Zoth was Chief Accounting Officer for PSINet, Inc. and Sodexho Marriott Services, Inc., both of which were publicly-held companies. She also served in various finance executive roles at Marriott International and PepsiCo, Inc. after spending almost a decade at Ernst & Young as an audit executive. Ms. Zoth is a certified public accountant and holds a bachelor’s of business administration degree in accounting from Texas Tech University.

“Lota’s extensive financial and operational background will be a valuable addition to our Board of Directors,” said Chris Rivera, President and Chief Executive Officer of Hyperion Therapeutics, Inc. “We look forward to her contributions as we build out our financing strategies with an eye towards accessing the public markets.”

About Hyperion Therapeutics
Hyperion Therapeutics is a fully-integrated specialty therapeutics company committed to becoming a global leader in the development and commercialization of hepatology and gastrointestinal therapies that address orphan or underserved patient populations with unmet medical needs. Hyperion’s commercial operations division currently markets two products in the United States for urea cycle disorder. The Company is also conducting two phase II trials, one in the chronic treatment of urea cycle disorder and the other in the treatment of acute hepatic encephalopathy. Hyperion is headquartered in South San Francisco, CA. For additional information, visit www.hyperiontx.com.


###


Press Contact:

Chris Rivera

President and CEO

Hyperion Therapeutics, Inc.

650-745-7802

Share On Twitter Linkedin